News
SalivaDirect and Ubiquitome Deliver Cost-Effective, Mobile SARS-CoV-2 Tests
June 8, 2021 – Testing people for SARS-CoV-2 (COVID-19) has just been made easier and more accessible with United States Food and Drug Administration (FDA) emergency use authorization (EUA) of the combination of SalivaDirect™ with Ubiquitome’s Liberty16 mobile real time-PCR.
 > Read More
New Zealand’s Ubiquitome Signs NIH RADx Contract
October 7, 2020 – New Zealand-based Ubiquitome is ramping up production of its mobile, real-time (RT) PCR technology with funding from the United States’ National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative.
Ubiquitome is the only NZ private company to be accepted into the highly competitive RADx and to receive federal funding through the NIH in recent years.
> Read More
Ubiquitome Targets Testing Travellers for COVID-19
May 8, 2020 – Ubiquitome is receiving just over half a million dollars in government funding to help with increasing the manufacturing capacity of its Liberty16 rapid COVID-19 testing device in Auckland.
Paul Pickering, chief executive of Ubiquitome, says the mobile device would be ideal for use in places like airports, pre-screening international travellers once borders reopen. Passengers could be tested and would get the result before their flight, indicating whether they should travel or not.
> Read More
Ubiquitome’s COVID-19 Fast Test Device in Spotlight
Auckland, New Zealand, March 27, 2020 – Ubiquitome’s ability to deliver fast test results for COVID-19 is attracting global inquires and top talent keen to get it to countries in desperate need.
Ubiquitome says, since the United Kingdom’s top COVID-19 research team revealed it was considering using Liberty 16 to test front line medical staff, international scientists have realised waiting more than an hour for test results is not necessary.
> Read More
